



Clene to Present at the Canaccord 45th Annual Growth Conference

August 5, 2025

SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, "Clene") and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at the Canaccord 45th Annual Growth Conference and host 1x1 investor meetings.

Date: August 12th, 2025

Time of Presentation: 3:30pm ET

Location: Boston, MA

Format: Presentation

1x1 Meetings: Please contact your Canaccord representative

A webcast of the presentation will be available on the "[Events](#)" section of the Clene website. Alternatively, one can register online to view the webcast here: [link](#).

About Clene

Clene Inc., (Nasdaq: CLNN) (along with its subsidiaries, "Clene") and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson's disease, and multiple sclerosis. CNM-Au8[®] is an investigational first-in-class therapy that improves central nervous system cells' survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8[®] is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on [X \(formerly Twitter\)](#) and [LinkedIn](#).

Investor Contact

Kevin Gardner

LifeSci Advisors

kgardner@lifesciadvisors.com

617-283-2856